A 40-year-old female with a history of depression and anxiety is currently taking Wellbutrin (bupropion) XL 300 mg once daily, Buspar (buspirone) 15 mg twice daily, and sertraline 50 mg once daily. What medication recommendations are appropriate?

Medication Recommendations for Triple Antidepressant Regimen

This patient is taking an unnecessarily complex and potentially problematic triple antidepressant regimen that should be simplified. The combination of bupropion 300mg, buspirone 30mg daily, and sertraline 50mg represents polypharmacy without clear evidence of superior efficacy, and the sertraline dose is subtherapeutic.

Primary Recommendation: Simplify the Regimen

Option 1: Optimize Sertraline Monotherapy (Preferred for anxiety-predominant presentation)

• Increase sertraline to 100-200mg daily (current 50mg is below the typical therapeutic range for depression)
• Taper and discontinue buspirone over 1-2 weeks
• Continue bupropion 300mg OR taper if anxiety worsens

Rationale: The 2023 ACP guidelines show no significant differences in efficacy between various second-generation antidepressants for depression 1. When augmentation strategies were compared, bupropion augmentation showed similar response and remission rates to buspirone augmentation, but buspirone had significantly higher discontinuation rates due to adverse events (20.6% vs 12.5%, p<0.001) 1, 2. For a patient with prominent anxiety, an SSRI at therapeutic doses is typically first-line.

Option 2: Bupropion + Sertraline Dual Therapy

• Increase sertraline to 100-150mg daily
• Continue bupropion 300mg daily
• Discontinue buspirone (least evidence-based component)

Rationale: While the 2016 ACP guidelines found no difference in depression severity reduction between bupropion and buspirone augmentation 2, buspirone adds complexity without clear benefit when already using two mechanistically distinct antidepressants. Small case series suggest bupropion-sertraline combinations can be effective in treatment-refractory depression 3, though this patient hasn't had an adequate trial of either medication at therapeutic doses.

Critical Safety Considerations

Serotonin Syndrome Risk

Monitor closely for serotonin syndrome with the current bupropion-sertraline combination. While bupropion is primarily a norepinephrine-dopamine reuptake inhibitor, it inhibits CYP2D6, potentially increasing sertraline levels and precipitating serotonin syndrome 4. Watch for: myoclonus, confusion, agitation, autonomic instability, altered consciousness.

Anxiety Worsening with Bupropion

Recent 2025 evidence indicates bupropion's effects on anxiety are mixed 5, 6:

• May improve anxiety symptoms in mild-to-moderate cases
• Can provoke anxiety due to stimulating properties, especially at higher doses
• SSRIs show modest advantage in patients with severe baseline anxiety 5

If anxiety worsens after simplification, consider switching entirely to an SSRI/SNRI rather than adding back buspirone.

Mania Risk

Bupropion carries risk of mood switching, particularly in undiagnosed bipolar disorder 7. Screen for: prior hypomanic episodes, family history of bipolar disorder, antidepressant-induced activation.

Why This Regimen Needs Revision

1. Subtherapeutic SSRI dosing: 50mg sertraline is below the 100-200mg range typically needed for depression
2. Redundant augmentation: Using both bupropion AND buspirone as augmentation agents lacks evidence support
3. Buspirone's limited role: Evidence shows buspirone augmentation has higher discontinuation rates and no superior efficacy compared to bupropion 1, 2
4. No failed adequate trials: Cannot assess treatment resistance when medications aren't at therapeutic doses

Implementation Algorithm

Step 1: Assess current symptom severity and predominant presentation

• If anxiety-predominant → favor SSRI optimization (Option 1)
• If depression-predominant with low energy → favor bupropion + SSRI (Option 2)

Step 2: Increase sertraline to 100mg daily immediately

Step 3: Taper buspirone 15mg BID → 15mg daily × 3-5 days → discontinue

Step 4: Reassess at 4-6 weeks

• If inadequate response: increase sertraline to 150-200mg
• If anxiety worsens significantly: consider tapering bupropion over 1-2 weeks

Step 5: If still inadequate response after 8-12 weeks at therapeutic doses, then consider evidence-based augmentation strategies per ACP guidelines 1

Common Pitfalls to Avoid

• Don't continue subtherapeutic dosing while adding augmentation agents
• Don't assume treatment resistance without adequate therapeutic trials (adequate dose × adequate duration)
• Don't overlook bipolar disorder before continuing/escalating bupropion
• Don't add benzodiazepines for anxiety during the transition—recent evidence shows buspirone efficacy is independent of benzodiazepine co-administration 8